Diffuse mesothelioma
Neurofibromatosis Type 2-Yes-Associated Protein and Transcriptional Coactivator With PDZ-Binding Motif Dual Immunohistochemistry Is a Reliable Marker for the Detection of Neurofibromatosis Type 2 Alterations in Diffuse Pleural Mesothelioma
Modern Pathology 2023 March [Link] Yan Li, Soo-Ryum Yang, Ying-Bei Chen, Prasad S Adusumilli, Ann Bialik, Francis M Bodd, Marc Ladanyi, Jessica Lopardo, Michael D Offin, Valerie W Rusch, William D Travis, Marjorie G Zauderer, Jason C Chang, Jennifer L Sauter Abstract Neurofibromatosis type 2 (NF2) loss occurs in approximately 30% to 50% of diffuse…
Read MoreNR4A3 fusions characterize a distinctive peritoneal mesothelial neoplasm of uncertain biological potential with pure adenomatoid/microcystic morphology
Genes, Chromosomes, and Cancer 2022 December 16 [Link] Abbas Agaimy, Luka Brcic, Laurence M Briski, Yin P Hung, Michael Michal, Michal Michal, G Petur Nielsen, Robert Stoehr, Andrew E Rosenberg Abstract A focal adenomatoid-microcystic pattern is not uncommon in peritoneal mesothelioma, but tumors composed almost exclusively of this pattern are distinctly rare and have not…
Read MoreMedical and surgical care of mesothelioma patients and their relatives carrying germline BAP1 mutations
Journal of Thoracic Oncology 2022 April 21 [Link] Michele Carbone, Harvey I Pass, Guntulu Ak, H Richard Alexander Jr, Paul Baas, Francine Baumann, Andrew M Blakely, Raphael Bueno, Aleksandra Bzura, Giuseppe Cardillo, Jane E Churpek, Irma Dianzani, Assunta De Rienzo, Mitsuru Emi, Salih Emri, Emanuela Felley-Bosco, Dean A Fennell, Raja M Flores, Federica Grosso, Nicholas…
Read MoreMulticenter study of diffuse pleural mesothelioma. Histopathological and immunohistochemical features
Medicina 2022 [Link] Claudia Poleri, Gabriela Acosta Haab, Nora Falcoff, Gabriela Guman, Liliana Dalurzo, Alejandro Iotti, María Eugenia Martín, Gloria Olmedo, Mercedes Rayá, Atilio Reginatto, Andrea Werbach, Gabriela Demelli, María José Labanca, Laura Leguina, María Florencia Mora Abstract The pathological diagnosis of diffuse pleural mesothelioma (DPM) contributes to treatment selection and clinical trials interpretation. To…
Read MoreA Critical Assessment of Current Grading Schemes for Diffuse Pleural Mesothelioma With a Proposal for a Novel Mesothelioma Weighted Grading Scheme (MWGS)
The American Journal of Surgical Pathology 2021 December 15 [Link] Talia L Fuchs, Angela Chou, Yagiz Aksoy, Mahiar Mahjoub, Amy Sheen, Loretta Sioson, Mahsa Ahadi, Anthony J Gill Abstract Although there is early support for schemes based on nuclear grade, necrosis and mitotic rate, there is currently no widely implemented grading system for diffuse pleural…
Read MoreUnusually favorable outcome of 6 consecutive patients with diffuse malignant peritoneal mesothelioma treated with repeated doses of intraperitoneal paclitaxel. A case series
Surgical Oncology 2020 June [Link] Paul H Sugarbaker, O Anthony Stuart Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a disease in transition. Two decades ago this cancer had a median survival of 1 year. Recent reports in selected patients show a 5-year survival of 70% and median survival not reached at 10 years. Methods:…
Read MoreCurcumin as an Anticancer Agent in Malignant Mesothelioma: A Review.
International Journal of Molecular Science 2020 March 7 [Link] Baldi A, De Luca A, Maiorano P, D’Angelo C, Giordano A Abstract Malignant mesothelioma is an infrequent tumor that initiates from the mesothelial cells lining of body cavities. The great majority of mesotheliomas originate in the pleural cavity, while the remaining cases initiate in the peritoneal…
Read MorePredictors and Outcomes of Surgery in Peritoneal Mesothelioma: an Analysis of 2000 Patients from the National Cancer Database.
Annals of Surgical Oncology 2020 January 31 [Link] Bijelic L, Darcy K, Stodghill J, Tian C, Cannon T Abstract INTRODUCTION: Diffuse malignant peritoneal mesothelioma (DMPM) is a rare malignancy associated with poor outcomes. Recent reports have shown longer survival with radical surgery, usually combined with intraperitoneal chemotherapy. However, surgical interventions in these patients have not…
Read MoreMalignant Diffuse Mesothelioma in Women: A Study of 354 Cases.
The American Journal of Surgical Pathology 2019 December 23 [Link] Pavlisko EN, Liu B, Green C, Sporn TA, Roggli VL Abstract We reviewed 354 cases of malignant diffuse mesothelioma (MM) in women from a database of 2858 histologically confirmed MM cases. There was a pleural predominance with 78% pleural MM and 22% peritoneal MM. The…
Read MoreSplicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
EBioMedicine 2018 December 20 [Link] Sciarrillo R1, Wojtuszkiewicz A2, El Hassouni B, Funel N, Gandellini P, Lagerweij T, Buonamici S, Blijlevens M, Zeeuw van der Laan EA, Zaffaroni N, Deraco M, Kusamura S, Würdinger T, Peters GJ, Molthoff CFM, Jansen G, Kaspers GJL, Cloos J, Giovannetti E Abstract INTRODUCTION: Therapeutic options for diffuse malignant peritoneal…
Read More